EMD 72000-024, NCT00113581: Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer |
|
|
| Completed | 1 | 26 | Europe | EMD 72000 (matuzumab) + ECX | Merck KGaA, Darmstadt, Germany | Esophageal Cancer, Gastric Cancer | 05/06 | 01/07 | | |
